Clinical Trial Update: Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting on humoral and cellular immune responses to herpes simplex glycoprotein D vaccine candidates derived from two different cell lin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Infection

Drugs mentioned

• Herpes simplex glycoprotein D vaccine candidate (cell line A) (glycoprotein D vaccine)
• Herpes simplex glycoprotein D vaccine candidate (cell line B) (glycoprotein D vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Prophylaxis Herpes Simplex | Phase 1, Phase 2 | Status: COMPLETED